BioVeda Capital

BioVeda Capital

This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Headquarters Location

Singapore, Singapore

About

This investor is located in Asia, Singapore. The primary office of this VC is located in Singapore.

Besides the listed founders, we have found 4 key employees of this fund in our database.

The country of its establishment and the country of its most frequent investments coincides - Singapore. However, start-ups from 1 other country can be found in the fund's portfolio. Also, a start-up has to be aged 2-3 years to expect investment from this fund. ASLAN Pharmaceuticals, MerLion Pharma, CXA Group are among the most popular portfolio start-ups of the fund. Among their most successful investment fields, we have identified Employee Benefits, Financial Services. Also, because of its portfolio diversification tendency, we can highlight 10 more industries for this fund. The fund has specific requirements for the number of founders in a start-up.

The fund usually invests in rounds together with 4-5 others. Along with BioVeda Capital, start-ups are often financed by Zillionize Angel, University of Manchester, TA Ventures. Other VCs who often invest in the same rounds are Temasek Holdings, Yasuda Enterprise Development, Vertex Ventures Southeast Asia & India. The investors in the following rounds are usually Sagamore Bioventures, Openspace Ventures, Morningside Group, and 2 VCs in total.

The average start-up valuation at the time of investment from BioVeda Capital is 5-10 millions dollars. BioVeda Capital participates, on average, in 15 percentage points more than the average amount of lead investments in other funds. This fund was the most active in 2002. The fund performance shows that this VC achieves 9 percentage points less exits in comparison to other VCs. The highest number of exits from this fund were in 2019. The most common rounds for this fund are in the range of 10 - 50 millions dollars. The fund typically enters into less than 2 deals annually.

Fund Activity

Not operative

Group Appearance [how often fund is operating separately from groups with shared interest]

100.0% of cases

Follow-on Index [how often fund is ready to support its portfolio startup at next rounds]

10.0% of cases

Average Multiplicator [the average ratio of the last valuation of portfolio startups to their total amount of financing raised]

x13.5

Average Portfolio Company
Exit Age [the average age of portfolio startups at which they go public or become acquired]

6.1 years

Success / Strategy Similarity
Index [the matching between fund's investment strategy and its proved successes in the form of portfolio startups high valuations]

0.3 out of 1

Number of Unicorns [amount of portfolio companies, which were valuated at more then $1B]

1

Funds Investing in Previous
Rounds

Zillionize Angel, University of Manchester, TA Ventures

Funds Investing in Following
Rounds

Sagamore Bioventures, Openspace Ventures, Morningside Group

If you have found a spelling error or the data isn't actual, please, notify us by selecting that text and pressing Ctrl+Enter.

Fund reviews
  • No reviews are submitted yet.
Crunchbase icon

Content report

The following text will be sent to our editors: